Glomerulonephritis  >>  Soliris (eculizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01221181: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Completed
1
6
US
Eculizumab, Eculizumab (Soliris®)
Columbia University, Alexion Pharmaceuticals
Dense Deposit Disease, Membranoproliferative Glomerulonephritis
10/11
10/11

Download Options